The clinical trial approval for the Group’s second generation of highly-effectiveabsorbed tetanus vaccine has been recently obtained from the National Medical Products Administration, which marks a new progress of the research and development of the vaccine.

The clinical trial approval for the Group’s suspension culture quadrivalent influenza vaccine (MDCK cells) with new technological route has been recently obtained from the National Medical Products Administration, which marks a new progress of the research and development of the vaccine. Currently, all influenza vaccines available on the domestic market are produced using chicken embryo technology. There have not been cell-based influenza vaccines approved for marketing. As a heavyweight key product, influenza vaccine (MDCK cells) is expected to become a new growth driver of the Group after its launch.

The 2024 Corporate Day event (the “Event”) of AIM Vaccine Co., Ltd. (“AIM Vaccine”or the “Group”) was successfully held on November 21, 2024.

The pre-application for marketing registration of the iterative serum-free rabies vaccine independently developed by the Group has been submitted to the National Medical Products Administration recently.

The application for clinical trial of the iterative-process highly-effective human diploid rabies vaccine developed by the Group has been submitted to the Center for Drug Evaluation (CDE) of National Medical Products Administration of China recently.

The application for drug marketing registration of the Group’s independently developed 13-valent pneumonia conjugate vaccine has been submitted to the National Medical Products Administration on October 31, 2024.

The board of directors of the Company (the “Board”) is pleased to announce that the clinical trial approval for the mRNA respiratory syncytial virus (RSV) vaccine developed by a controlled subsidiary of the Group, Liverna Therapeutics Inc., has been recently obtained from the National Medical Products Administration, which marks a new progress of the research and development of the vaccine.

The board of directors of the Company (the “Board”) is pleased to announce that the Group has recently received a notice from the National Institutes for Food and Drug Control of the PRC (中國食品藥品檢定研究院) on the serum antibodies test results of Phase III clinical trial of iterative serum-free rabies vaccine. To date, the unblinding and statistical analysis work for data of Phase III clinical trial of the iterative serum-free rabies vaccine of the Group has been completed. The research results showed that the iterative serum-free rabies vaccine developed by the Group has good immunogenicity and safety and has met the pre-defined clinical objectives.

The board of directors of the Company (the “Board”) is pleased to announce that the Group has submitted the official application to the Center for Drug Evaluation (CDE) of National Medical Products Administration of China for clinical trials for quadrivalent influenza virus vaccine (MDCK Cells) in August 2024. Currently, all influenza vaccines available on the domestic market are produced using chicken embryo technology. There have not been cell-based influenza vaccines approved for marketing. Organizations such as the World Health Organization, the U.S. Food and Drug Administration, and governments of several countries worldwide advocate for the adoption of animal cell culture technology to replace the traditional chicken embryo technology in production of influenza vaccines.